Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Ainos Secures Seven New Patents In Europe, Germany, Taiwan, And China, Enhancing Its AI Nose Digital Olfaction Platform For Robotics Applications

Author: Benzinga Newsdesk | September 30, 2025 08:32am

Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced it has secured seven new patents in Europe, Germany, Taiwan and China that strengthen its AI Nose digital olfaction platform and its applications in robotics. With these additions, Ainos now holds 123 active patents across key technologies, covering the U.S., Europe, Germany, Japan, Taiwan, and China.

AI Nose Expands Across High-Value Applications

Ainos' AI Nose platform is rapidly broadening its commercial opportunities across multiple industries:

Healthcare and Senior Care: Provides real-time detection and continuous monitoring to protect patients and seniors.

Semiconductors: Detects subtle scent anomalies to optimize processes, improve yield, and enhance safety.

Smart Factories: Equips fully automated production lines with the ability to "smell," enabling efficient maintenance and greater process stability.

Robotics: Adds the long-missing sense of smell to machines, allowing robots to "see, hear, touch-and now smell" for service, security, disaster response, and smart city applications.

"AI Nose digitizes smell, the critical human sense that has been absent from machines-until now," said Eddy Tsai, Chairman, President, and CEO of Ainos. "Our patents form a deep moat around AI Nose technology, covering product design, internal structures, system configurations, and core operating principles. This robust protection secures our leadership in AI-powered electronic nose and accelerates commercial adoption across healthcare, smart manufacturing, automation, and robotics."

Ainos has also filed additional patent applications in major markets to expand its IP moat. The Company is advancing its SmellTech-as-a-Service business model and remains on track to achieve its 2026 commercialization milestone, bringing digital olfaction into the era of AI and smart manufacturing.

About AI Nose

AI Nose digitizes scent into Smell ID, an AI-driven scent intelligence. This full-stack electronic nose (e-nose) platform combines precision MEMS sensor arrays with proprietary AI algorithms, aiming to detect scent at parts-per-billion (ppb) sensitivity. Smell ID then converts analog scent data into actionable insights, while the proprietary smell language model (SLM) learns complex scent patterns. Backed by a 13-year scent data moat and deep medtech expertise, AI Nose aims to deliver continuous monitoring, predictive analytics, and instant alerts to boost safety, quality, and efficiency. To be delivered as SmellTech-as-a-Service, it aims to offer subscription access to ongoing scent intelligence, analytics, and real-time alerts, turning the invisible into strategic advantage.

Posted In: AIMD AIMDW

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist